Monday, May 4, 2020
10:32 AM EST – Oncolytics Biotech® Inc. : Currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an abstract for an electronic-poster (ePoster) to be presented as part of the ESMO Breast Cancer Virtual Meeting on May 23 & 24. The abstract highlights preliminary data on viral replication and a pelareorep-induced adaptive immune response in tumors from the Company’s window-of-opportunity study, AWARE-1. The study combines the appropriate intervention for their breast cancer sub-type, plus pelareorep, with or without atezolizumab (Tecentriq®), followed by surgery in early-stage breast cancer. Oncolytics Biotech® Inc. (T.ONC ) shares were up $0.15 at 2.27.
Stocks in Play: Oncolytics Biotech® Inc., Mon, 04 May 2020 10:42:59 EST